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ABSTRACT 23 
Dengue is the most prevalent arthropod-borne viral disease affecting humans, with 24 
severe dengue typified by potentially fatal microvascular leakage and hypovolaemic shock. 25 
Blood vessels of the microvasculature are composed of a tubular structure of endothelial cells 26 
ensheathed by perivascular cells (pericytes). Pericytes support endothelial cell barrier 27 
formation and maintenance through paracrine and contact-mediated signalling, and are critical 28 
to microvascular integrity. Pericyte dysfunction has been linked to vascular leakage in 29 
noncommunicable pathologies such as diabetic retinopathy, but has never been linked to 30 
infection-related vascular leakage. Dengue vascular leakage has been shown to result in part 31 
from the direct action of the secreted dengue virus (DENV) non-structural protein NS1 on 32 
endothelial cells. Using primary human vascular cells, we show here that NS1 also causes 33 
pericyte dysfunction, and that NS1-induced endothelial hyperpermeability is more pronounced 34 
in the presence of pericytes. Notably, NS1 specifically disrupted the ability of pericytes to 35 
support endothelial cell function in a 3D microvascular assay, with no effect on pericyte viability 36 
or physiology. These effects are mediated at least in part through contact-independent 37 
paracrine signals involved in endothelial barrier maintenance by pericytes. We therefore 38 
identify a role for pericytes in amplifying NS1-induced microvascular hyperpermeability in 39 
severe dengue, and thus show that pericytes can play a critical role in the aetiology of an 40 
infectious vascular leakage syndrome. These findings open new avenues of research for the 41 
development of drugs and diagnostic assays for combating infection-induced vascular 42 
leakage, such as severe dengue. 43 
 44 
 45 
 46 
 47 
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IMPORTANCE 48 
The World Health Organisation considers dengue one of the top ten global public 49 
health problems. There is no specific antiviral therapy to treat dengue virus and no way of 50 
predicting which patients will develop potentially fatal severe dengue, typified by vascular 51 
leakage and circulatory shock. We show here that perivascular cells (pericytes) amplify the 52 
vascular leakage-inducing effects of the dengue viral protein NS1 through contact-53 
independent signalling to endothelial cells. While pericytes are known to contribute to 54 
noncommunicable vascular leakage, this is the first time these cells have been implicated in 55 
the vascular effects of an infectious disease. Our findings could pave the way for new 56 
therapies and diagnostics to combat dengue, and potentially other infectious vascular leakage 57 
syndromes. 58 
 59 
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INTRODUCTION 70 
Dengue virus (DENV) is a serocomplex of four viruses (DENV-1-4) and the most 71 
prevalent arthropod-borne virus (arbovirus) affecting humans. Almost half the world’s 72 
population lives in at-risk areas across the tropics and subtropics, with an estimated 390 73 
million infections and 96 million symptomatic cases per year (1). Dengue patients experience 74 
a range of symptoms including high fever, leucopoenia, maculopapular rash, retro-orbital pain, 75 
arthralgia and myalgia (2, 3). A minority of patients (approximately 500,000 cases per year) 76 
develop severe dengue, typified by cardiovascular complications such as plasma leakage 77 
(e.g. pleural effusion, oedema) and/or bleeding (haemorrhage) manifesting during 78 
defervescence that can lead to hypovolaemic shock, organ failure and death (2, 3). Dengue 79 
haemorrhage is associated with platelet dysfunction and a consequent thrombocytopaenia, 80 
and/or disseminated intravascular coagulation (4). Fluid replacement therapy and other 81 
supportive treatments reduce the death rate, but there are no specific drugs to treat dengue 82 
and no diagnostic measure to predict the development of the life-threatening severe dengue 83 
(2-4). 84 
At a microvascular level, the precise mechanisms leading to vascular leakage in 85 
severe dengue remain incompletely understood. A dysregulated cytokine response has been 86 
proposed to be a major contributor to vascular hyperpermeability, especially in heterotypic 87 
secondary infections with a different DENV serotype to the first infection (3, 5, 6). Antibodies 88 
against the viral non-structural protein NS1 have also been shown to bind to endothelial cells 89 
in secondary infections, causing their apoptosis (7-9). In addition, NS1 protein is abundantly 90 
secreted into patient serum and has been shown to directly induce endothelial cell 91 
hyperpermeability (10, 11). Serum NS1 concentrations in dengue patients vary widely. 92 
Although concentrations as high as 15,000 ng/ml have been recorded in some patients, 93 
concentrations of 10-1,000 ng/ml are more typical, with one study suggesting that levels above 94 
600 ng/ml may be predictive of severe disease (12-14). NS1 enters endothelial cells through 95 
dynamin- and clathrin-dependent endocytosis and induces the expression of secreted cellular 96 
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sialidases, heparanase and cathepsin L that cleave components of the endothelial cell 97 
glycocalyx reducing the integrity of the barrier (15-18). Inhibitors of sialidases and 98 
heparanases reduce NS1-dependent endothelial hyperpermeability in vitro, and NS1 99 
vaccination has been shown to protect against vascular leakage in vivo (11, 17, 19). In addition 100 
to these direct effects on the microvascular endothelium, other pathogenic mechanisms 101 
contributing to dengue plasma leakage and haemorrhage have also been reported (20), as 102 
reviewed in (21). 103 
The published mechanistic studies into NS1-induced dengue vascular leakage 104 
primarily assessed endothelial cell function. However, the vessels affected in severe dengue 105 
in vivo, primarily capillaries and post-capillary venules, are comprised of an endothelial cell 106 
lining surrounded by perivascular cells (pericytes) embedded within the basement membrane 107 
(Fig 1A) (22, 23). There is a dynamic relationship between pericytes and endothelial cells, with 108 
two-way paracrine signalling as well as contact-mediated communication facilitated by 109 
pericyte pseudopod extensions that wrap around the endothelial cells (24). Pericytes are 110 
essential in both blood vessel formation to drive endothelial cell migration, proliferation and 111 
maturation, and in homeostasis for the maintenance and regulation of the endothelial barrier 112 
in established vessels (25, 26). Pericyte deficiency is perinatally lethal in mouse models due 113 
to widespread vascular leakage and aneurysms (27). In established vessels, pericyte 114 
dysfunction leads to microvascular hyperpermeability, such as in diabetic retinopathy where 115 
chronic exposure to heightened glucose levels due to unmanaged diabetes causes capillary 116 
occlusions, microaneurysms and blindness (28). To date, the role of pericytes in the aetiology 117 
of vascular hyperpermeability caused by an infectious disease has not been described. 118 
Here, we use microvascular hyperpermeability induced by DENV NS1 as a model to 119 
demonstrate a crucial role for pericytes in amplifying an infectious haemorrhagic syndrome. 120 
We show that DENV-2 NS1 induces hyperpermeability in in vitro co-cultures of primary 121 
pericytes and primary endothelial cells, and that the observed hyperpermeability is greater 122 
than for endothelial cells cultured alone. NS1 does not broadly affect all pericyte functions, but 123 
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rather specifically reduces the capacity of pericytes to support endothelial cell function in 3D 124 
microvascular models. Finally, we demonstrate that NS1-induced hyperpermeability is not 125 
dependent on endothelial-pericyte cell contact and is at least partially mediated through effects 126 
on paracrine signalling. Our findings could inform new strategies for developing diagnostics 127 
and treatments for severe dengue, and could have wide-reaching implications for the role of 128 
pericytes in other infectious vascular leakage syndromes. 129 
 130 
RESULTS 131 
NS1 triggers pericyte dysfunction and hyperpermeability in vascular cell co-132 
cultures 133 
We used trans-endothelial electrical resistance (TEER) as a measure of the strength 134 
of a cell monolayer barrier. In line with previous studies (11, 17), we found that treatment with 135 
DENV-2 NS1 reduced the barrier function of primary human umbilical vein endothelial cells 136 
(HUVECs) starting from 12 h post-treatment (Fig 1B). The magnitude of this NS1 effect was 137 
comparable to that of the vasodilatory cytokine TNF-α, here used as a positive control (Fig 138 
1B). 139 
Next, we wanted to explore whether pericytes, which are known to provide 140 
fundamental control of microvascular permeability by regulating endothelial cell function (25), 141 
contribute to NS1-induced hyperpermeability. Previously, we isolated a population of 142 
perivascular cells from the microvasculature surrounding human saphenous veins that 143 
expressed bona fide pericyte markers and supported endothelial cell function and 144 
angiogenesis in vitro and in vivo (29). Here, we established an in vitro model of the 145 
microvascular barrier in which HUVECs were co-cultured with saphenous vein pericytes 146 
(SVPs) in semi-contact, on either side of a porous membrane within a transwell system (Fig 147 
1Cii). In this experimental set-up, pericytes and endothelial cells interact both via direct cell-148 
to-cell contacts, through the membrane pores (30, 31) and via paracrine signalling mediated 149 
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by soluble signalling molecules diffusing through the membrane (30, 32). Cells are not able to 150 
migrate through the pores of the membranes used in this study. Co-culture of endothelial cells 151 
with pericytes significantly increased endothelial barrier function compared to endothelial cells 152 
cultured alone, thus recapitulating the regulatory function of pericytes (Fig 1C). Treatment of 153 
these endothelial-pericyte co-cultures with 500 ng/ml DENV-2 NS1 significantly reduced 154 
endothelial barrier function (Fig 1C). This effect was evident from 8 h post-treatment and by 155 
16 h the TEER of the co-cultures was indistinguishable from that of endothelial cells cultured 156 
alone. This indicates that NS1 completely abolished the ability of pericytes to support the 157 
barrier function of endothelial cells in this system. In contrast, ovalbumin did not affect 158 
permeability of the co-culture (Fig 1D), confirming the specificity of the observed pericyte 159 
dysfunction induced by DENV-2 NS1. 160 
Notably, the absolute magnitude of the TEER decrease was significantly higher in the 161 
co-cultures compared to endothelial cells cultured alone, indicating a stronger effect of NS1 162 
on permeability in the presence of pericytes (Fig 1Ei). Even when we accounted for the higher 163 
absolute TEER of the endothelial-pericyte co-cultures by normalising to the respective 164 
untreated controls, the decrease in barrier function in the co-culture was almost double that of 165 
endothelial cell monocultures at 20 h and 24 h post-treatment (Fig 1Eii). 166 
Taken together, these results indicate that DENV-2 NS1 induces extensive dysfunction 167 
in primary human pericytes, leading to their inability to support endothelial cell barrier function. 168 
Furthermore, the effect NS1 has on permeability is more pronounced in the presence of 169 
pericytes, indicating that the presence of pericytes amplifies NS1-dependent microvascular 170 
hyperpermeability. 171 
NS1 disrupts the pericyte interaction with and support of the endothelial network  172 
We next wanted to determine whether NS1 acts by disrupting the ability of pericytes 173 
to functionally support endothelial cells. Angiogenesis, the formation of new blood vessels 174 
from existing ones, is a complex process requiring precisely regulated reciprocal crosstalk 175 
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between endothelial cells, which elongate and migrate to form new lumens, and pericytes, 176 
which ensheathe the branches and confer maturity to the new structures (32). Endothelial cells 177 
cultured in a 3D Matrigel substrate organise into capillary-like structures, and the maturation 178 
of these structures upon co-culture with pericyte is an established readout for the ability of 179 
pericytes to support endothelial cell and capillary functionality (29). In our hands, endothelial 180 
cells cultured on Matrigel formed abundant capillary-like structures after 6 h and the presence 181 
of pericytes visibly increased the thickness of the branches of these structures (Fig 2A). This 182 
increase in branch width is due to the physical association of pericytes with the endothelial 183 
structures, and the secretion of pro-angiogenic factors by pericytes directly stimulating the 184 
endothelium (29). 185 
Treatment of 3D endothelial-pericyte co-cultures with 500 ng/ml DENV-2 NS1 caused 186 
a reduction in branch width (Fig 2A), indicating a dysfunctional interaction between endothelial 187 
cells and pericytes. Quantification of NS1’s effect revealed a dose-dependent decrease in 188 
branch width, with doses above 300 ng/ml completely abolishing the contribution of pericytes 189 
to capillary-like structure formation (Fig 2B and 2Ci). In contrast, treatment with ovalbumin 190 
(“ova”) did not affect the endothelial-pericyte interaction in Matrigel (Fig 2Cii), demonstrating 191 
the specificity of the NS1 effect. Furthermore, branch width was not impacted by NS1 192 
treatment when endothelial cells were cultured in the absence of pericytes, indicating that NS1 193 
specifically interferes with the ability of pericytes to support the endothelium rather than the 194 
intrinsic angiogenic capacity of endothelial cells (Fig 2Ciii). Taken together, our data suggest 195 
that the amplified effect NS1 has on endothelial permeability in the presence of pericytes is 196 
due to a disruption of pericyte functionalities required for maintenance of the microvascular 197 
architecture.  198 
NS1 does not broadly disrupt all pericyte functions 199 
Our results demonstrate a robust effect of NS1 on pericyte function and in particular 200 
on the capacity of pericytes to support endothelial capillary-like structures and barrier function, 201 
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two defining roles of pericytes. In order to exclude that the observed effect is due to a reduced 202 
viability of the pericyte or the endothelial populations, we treated each cell type separately 203 
with a range of NS1 concentrations (50-500 ng/ml). NS1 treatment for 48h did not affect cell 204 
growth or viability in either endothelial cells or pericytes (Fig 3A).  205 
In order to support the microvascular architecture, pericytes must be able to migrate 206 
along capillaries. For this reason, we tested the intrinsic migratory capacity of pericytes upon 207 
treatment with NS1. DENV-2 NS1 concentration as high as 1,000 ng/ml had no effect on 208 
pericyte migration compared to the untreated control in a scratch assay measuring ‘wound’ 209 
closure following manual disruption of the cell monolayer (Fig 3B). These data further support 210 
our finding that NS1 specifically affects the endothelial-pericyte interaction. 211 
NS1 impacts pericyte paracrine signalling that supports the endothelial barrier 212 
Pericytes regulate endothelial permeability through cell-cell interactions and paracrine 213 
signalling (25). In order to assess the paracrine contribution of pericytes to endothelial barrier 214 
function, we modified our TEER assay by seeding pericytes on the bottom of the well instead 215 
of on the membrane. This prevents any contact between endothelial cells and pericytes across 216 
the porous membrane. In this non-contact TEER, co-culture of endothelial cells with pericytes 217 
increased endothelial barrier function to a similar extent to that observed in semi-contact 218 
TEER (Fig 4A, compared to Fig 1C). This confirms that pericytes’ contribute to the capillary 219 
barrier is not simply as an additional physical layer, but as a master regulator of endothelial 220 
permeability. Treatment with 500 ng/ml DENV-2 NS1 decreased the resistance of the 221 
endothelial cell monolayer in the non-contact co-culture starting at 8 h post-treatment, and 222 
from 12 h post-treatment the contribution of pericytes to endothelial barrier function was 223 
completely ablated (Fig 4A). Furthermore, neither the absolute nor the relative effect size of 224 
NS1 treatment was significantly different when comparing the contact and non-contact co-225 
cultures (Fig 4B), indicating that the effect of NS1 is mediated at least in part through paracrine 226 
modulators of endothelial barrier function.  227 
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 228 
DISCUSSION 229 
Here, we have described a role for pericytes in amplifying the hyperpermeability-230 
inducing effects of DENV-2 NS1 on endothelial cells in vitro, and in doing so demonstrated 231 
that pericytes play a crucial role in the aetiology of an infectious haemorrhagic syndrome. NS1 232 
had no effect on pericyte viability or migration, suggesting that NS1 specifically reduces the 233 
capacity of pericytes to support endothelial cell functions required for microvascular barrier 234 
formation and maintenance. We furthermore demonstrated that the effects of NS1 are at least 235 
partially the result of altered paracrine signalling between pericytes and endothelial cells. 236 
Since pericytes are an essential component of the microvascular architecture, we propose 237 
that pericytes play a crucial role in the aetiology of severe dengue. Interestingly, the distantly 238 
related flavivirus Japanese encephalitis virus (JEV) was recently shown to infect pericytes in 239 
the blood-brain barrier, where pericytes are also fundamental in maintaining the integrity of 240 
the barrier, allowing the virus to gain access to the brain to cause encephalitis (33). Pericytes 241 
may therefore play a wider role in the pathogenesis of flaviviruses that lead to diverse 242 
symptomatic outcomes. 243 
Our data strongly suggest that NS1 interferes with the dynamic crosstalk between 244 
endothelial cells and pericytes. The specific molecular mechanisms and factors mediating the 245 
NS1-dependent hyperpermeability remain unknown. For example, N-glycosylation of NS1 at 246 
position 207 is required for endocytosis into endothelial cells and hence the subsequent 247 
degradation of the glycocalyx that results in endothelial cell permeability (15). Whether NS1 248 
glycosylation is similarly important for the interaction between NS1 and pericytes is not known 249 
and would be interesting to investigate further. On the host side,  among several vasoactive 250 
molecules reported to be overrepresented in dengue patients, vascular endothelial growth 251 
factor (VEGF) has been shown to be upregulated twenty-fold compared to healthy controls 252 
(6). VEGF is abundantly (but not exclusively) secreted by pericytes to control endothelial cell 253 
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angiogenesis and negatively regulates pericyte function (34, 35). Platelet-derived growth 254 
factor BB (PDGF-BB), a critical regulator of pericyte association with the endothelium, was 255 
also upregulated 20-60-fold in dengue patients, with a further increase at defervescence in 256 
patients with severe dengue (36). This timing coincides with the development of severe 257 
symptoms and is suggestive of an endothelial response to pericyte dysfunction. Finally, low 258 
levels of angiopoietin 1 (Ang1) and elevated levels of its antagonist angiopoietin 2 (Ang2) have 259 
been associated with dengue vascular leakage (5, 37), and the Ang1:Ang2 ratio has been 260 
proposed as a diagnostic marker for patients at risk of developing severe dengue (38). Ang1 261 
is secreted by pericytes and platelets to increase endothelial barrier function (32), while Ang2, 262 
produced by endothelial cells and affecting pericyte coverage, is known to cause pericyte 263 
dropout in diabetic retinopathy (32, 39). It is tempting to speculate that one or more of these 264 
factors clinically associated with severe dengue might be indicative of a perturbation of 265 
pericyte function by NS1 in vivo. Exploring these various potential mechanisms underlying our 266 
observed effects of NS1 on the endothelial-pericyte interaction will provide fruitful avenues for 267 
future investigation. 268 
We propose a mechanism whereby, early during DENV infection, NS1 secreted into 269 
patient serum induces well-described direct effects on endothelial cells causing local 270 
permeability that allow NS1 to gain access to pericytes on the apical side of the endothelium 271 
(Fig 4i-iii). Subsequent effects of NS1 on pericytes cause a dysregulation of paracrine 272 
signalling between pericytes and endothelial cells that leads to pronounced and potentially 273 
life-threatening hyperpermeability that manifests during defervescence (Fig 4iv). In patients 274 
that recover, the integrity of the microvascular endothelium is restored as pericytes regain the 275 
ability to support endothelial cell functions crucial to endothelial barrier formation and 276 
maintenance (Fig 4v). Indeed, our experimental set-up specifically mimics a scenario in which 277 
NS1 targets both endothelial cells and pericytes concurrently following permeabilisation of the 278 
endothelial barrier, since we added NS1 to both sides of the transwell membrane (Fig 1Cii, 279 
4Aii). It is also feasible that NS1, which is endocytosed by endothelial cells (15), may 280 
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additionally access pericytes via transcytosis through endothelial cells prior to vascular 281 
permeabilisation in vivo, however this hypothesis remains to be tested. It seems unlikely that 282 
NS1 can target pericytes in vivo without first impacting on endothelial cells given that the major 283 
sites of DENV replication (and hence NS1 production) are monocyte-derived immune cells 284 
that secrete NS1 directly into the circulation. It is also feasible that pericyte function is indirectly 285 
disrupted due to a perturbation of endothelial cell signalling to pericytes by NS1, and this 286 
remains to be investigated. 287 
Concentrations as high as 15,000 ng/ml of NS1 have been observed in the serum of 288 
dengue patients, however patients with severe dengue most commonly have serum NS1 289 
levels ranging between 10-1,000 ng/ml (12-14). In our hands, NS1 affected the ability of 290 
pericytes to support endothelial cell function in 3D microvascular co-cultures at concentrations 291 
as low as 300 ng/ml (Fig 2C). To our knowledge, this is the lowest concentration at which 292 
microvascular effects of NS1 have been demonstrated in vitro. Furthermore, in endothelial-293 
pericyte co-cultures, the observed reduction in TEER upon treatment with 500 ng/ml of NS1 294 
is dramatically larger compared to endothelial cells cultured alone (Fig 1E). We therefore 295 
propose that modelling the essential role pericytes play in maintaining the microvascular 296 
endothelial barrier improves the ability of in vitro models of dengue hyperpermeability to 297 
recapitulate the effects of NS1 at more patient-relevant NS1 concentrations. Studying the 298 
effects of NS1 in our improved endothelial-pericyte co-culture system may identify novel 299 
molecular pathways and cellular mechanisms of dengue microvascular leakage that could 300 
facilitate the development of new diagnostics and treatments for severe dengue. Furthermore, 301 
our findings pave the way for future studies into the contribution that pericytes may make to 302 
the pathogenesis of other infectious diseases manifesting with symptoms of microvascular 303 
leakage. 304 
 305 
MATERIALS AND METHODS 306 
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Cell culture 307 
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (Basel, 308 
Switzerland). Saphenous vein pericytes (SVPs) were isolated from patient-derived saphenous 309 
vein adventitial vasa vasorum by enzymatic digestion using CD34+CD31- selection as 310 
described in our previous publication (29). Both cell types were cultured in endothelial growth 311 
medium-2 (EGM-2; PromoCell, Heidelberg, Germany) and maintained at 37˚C with 5% CO2. 312 
SVPs were grown on 1% fibronectin and 0.05% gelatin coated flasks (v/v). Cells were grown 313 
to 80% confluence and then passaged and used up to passage 8 for experiments.  314 
Recombinant proteins 315 
Human embryonic kidney 293 (HEK293)-produced DENV-2 NS1 was purchased from 316 
the Native Antigen Company (Kidlington, UK). Recombinant NS1 used between 50 and 1,500 317 
ng/ml as indicated in the figures and figure legends. Ovalbumin (Invivogen, San Diego, USA) 318 
was used as negative control at 500 ng/ml and TNF-α (Peprotech, Rocky hill, USA) as a 319 
positive control at 100 ng/ml. 320 
Matrigel angiogenesis assay 321 
Each well of a 96 well plate was coated with 30 μl of growth factor-reduced Matrigel 322 
(Corning, Corning, USA) on ice and allowed to solidify at 37˚C for 30 minutes. Single cultures 323 
of 2 x 104 cells/well of HUVECs or co-cultures of 1.5 x 104 cells/well of HUVECs and 0.5 x 104 324 
of SVPs were seeded on top of the Matrigel. Three brightfield images were taken from each 325 
well 6 h after treatment.  326 
Trans-endothelial electrical resistance (TEER) 327 
Millicell transwell inserts for 24-well plates (0.4 µm pores, Merk Millipore, Watford, UK) 328 
were coated with 1% fibronectin on both sides. Single cultures were established by seeding 1 329 
x 105 HUVECs per insert on one side of the transwell. For contact co-cultures, 2.5 x 104 SVPs 330 
per insert were seeded on the other side of the transwell, 24 h later. For non-contact co-331 
cultures, SVPs were alternatively seeded at the bottom of the 24-well plate. Cells were 332 
cultured to confluence and 50% of the medium was changed every 48 hours. Cells were 333 
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treated by removing 50% of the culture medium from both the well and the transwell insert, 334 
and making up the volume with fresh medium containing recombinant NS1 or control proteins. 335 
Concentrations shown in figures are final concentrations. TEER readings were taken using a 336 
Millicell ERS-2 Voltohmeter (Merk Millipore) immediately after treatment (0 h) and every 4 h 337 
for 24 h thereafter. Absolute TEER was calculated by subtracting the blank and multiplying by 338 
the well area; relative TEER was derived by dividing all values by the value of the HUVEC 339 
mono-cultures at each time point. 340 
Migration assay (wound healing) 341 
SVPs were seeded in 48-well plates and allowed to grow to confluence, at which point 342 
the monolayer was scratched using a 10 µl pipette tip. The culture medium was changed to 343 
remove detached cells and treatments as indicated in endothelial basal medium (EBM, 344 
PromoCell) in the presence of 2 mM hydroxyurea to prevent cell proliferation. Pictures of the 345 
scratches were taken in the same positions every 4 h. Gap closure was calculated as the 346 
percentage of the distance travelled by the cell front divided by the initial size of the gap and 347 
normalised to the positive control within each replicate. The positive control was pericytes 348 
grown in culture medium containing a full complement of growth factors. 349 
Cell viability assay 350 
HUVECs and SVPs were seeded in 96-well plates at 7 x 103 cells/well and 2 x 103 351 
cells/well respectively. After overnight adhesion, cells were treated with recombinant proteins 352 
for 24 or 48 h. AlamarBlueTM (ThermoFisher Scientific, Waltham, MA USA) was then added 353 
1:10 into the culture medium and fluorescence measured after 3 h using a spectrophotometer 354 
(excitation: 545nm, emission: 584nm). Relative viability was calculated in relation to the 355 
negative control. 356 
Microscopy and image analysis 357 
Images were captured using either Eclipse Ts2 (Nikon, Tokyo, Japan) or EVOS Cell 358 
Imaging System (ThermoFisher) inverted microscopes. All images for a single analysis were 359 
collected using the same settings. For 3D microvascular cultures in Matrigel, branch width 360 
values were calculated manually using Fiji (ImageJ) image analysis software (National 361 
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Institutes of Health, Bethesda, MA USA) (Fig 2B). For each branch an average of the manual 362 
measurements at the thinnest and thickest point was taken. The mean width of all branches 363 
observed in the three micrographs from a single well of the 96-well plate were taken as one 364 
technical replicate; biological replicates were from independently set up experiments. On 365 
average, approximately 100 branches were measured per condition for each experiment. To 366 
avoid bias, a subset of images from each experiment was blinded and independently verified 367 
by another lab member. All width measurement data are minimum N = 3, n = 3. 368 
Statistical analysis 369 
Values are reported as mean±SEM. Experiments were repeated with a minimum of 370 
three independent biological replicates and three technical repeats within each replicate. 371 
Statistical analyses were performed with GraphPad Prism 8 software (GraphPad Software 372 
Inc, San Diego, CA USA). For Fig 1B, 1C, 3B and 4A, statistical analysis was by two-way 373 
repeated-measures ANOVA with Dunnett correction for multiple comparisons. Fig 1D, 1E and 374 
4B were analysed by two-way repeated-measures ANOVA with Sidak correction for multiple 375 
comparisons. Fig 2Ci, 2Cii and 3A were analysed by one-way ANOVA with Dunnett correction 376 
for multiple comparisons. Fig 2Ciii was analysed by unpaired Student’s t test. 377 
Figures 378 
Graphs were plotted in GraphPad Prism 8 software. Illustrations were created with 379 
BioRender.com (Toronto, ON Canada). Figures were prepared in Adobe Illustrator (Adobe 380 
Systems, San Jose, CA USA). Images were cropped, annotated and modified to optimise 381 
brightness and contrast only.  382 
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FIGURE LEGENDS 536 
Fig 1. NS1 increases the permeability of an endothelial cell monolayer to a 537 
greater degree in the presence of co-cultured pericytes. (A) Cross-sectional illustration of 538 
the microvascular architecture, with pericytes (SVPs) supporting the maintenance of the 539 
endothelial barrier by endothelial cells (ECs). (B) Impact of treatment with purified recombinant 540 
TNF-α or DENV-2 NS1 on endothelial cell monolayer permeability over time as measured by 541 
TEER (trans-endothelial electrical resistance). At each individual time point, TEER values are 542 
normalised to untreated endothelial cells. (Bii) Experimental set-up for TEER measurements 543 
of endothelial cells cultured alone. (C and D) Enhancement of endothelial cell barrier function 544 
in co-culture with pericytes, and impact of treatment with DENV-2 NS1, TNF-α (C) or 545 
ovalbumin (“ova”) (D) on permeability of the co-culture over time. At each individual time point, 546 
TEER values are normalised to untreated endothelial cells cultured in the absence of pericytes 547 
(“EC alone”). (Cii) Experimental set-up of endothelial-pericyte co-cultures for data shown in 548 
panels C and D. (E) NS1-dependent decrease in TEER for endothelial cells cultured alone or 549 
in the presence of pericytes shown as absolute magnitude change in TEER (i) or percentage 550 
decrease relative to the respective untreated mono- or co-cultures (ii). All data minimum N = 551 
3; n = 3. Error bars represent standard error of the mean. * P < 0.05; ** P < 0.01; *** P < 0.001. 552 
In Fig 1B, indicated significance is for NS1 treatment versus untreated endothelial cells. In Fig 553 
1C and 1D, the difference between “EC alone” and “untreated” (co-cultures) is significant at P 554 
< 0.05. In Fig 1C, significant differences from “untreated” (co-cultures) are shown above the 555 
line for NS1 treatment and below the line for TNF-α treatment. 556 
 557 
Fig 2. NS1 disrupts pericyte’s ability to support endothelial ‘capillary’ structures 558 
in a 3D microvascular model. (A) Representative images of endothelial cells forming 559 
capillary-like structures in 3D Matrigel culture in the presence (“EC + SVP”) or absence (“EC 560 
alone”) of pericytes, with or without treatment with 500 ng/ml DENV-2 NS1. Scale bars 561 
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represent 400 µm. (B) Method of quantifying mean width of capillary-like structures in 3D 562 
Matrigel cultures using ImageJ. Dashed lines indicate branches (quantified); arrows indicate 563 
nodes where branches join together (not quantified). Branches were defined as containing 564 
elongated capillary-like endothelial cells, while nodes contained only aggregated non-565 
elongated endothelial cells. For each branch, an average of the manual measurements at the 566 
thinnest and thickest point was taken. The mean width of all branches across three 567 
micrographs taken from one well in a 96-well plate was taken as one technical replicate; 568 
biological replicates were from independently set up experiments. (C) Quantification of mean 569 
width of capillary-like structures in endothelial-pericyte co-cultures (i, ii) or endothelial cells 570 
cultured alone (iii) that were treated with NS1 or ovalbumin (“ova”) or left untreated (“mock”). 571 
Measurements are normalised to untreated endothelial cells cultured in the absence of 572 
pericytes (“EC alone”). Unless specified, recombinant protein concentration was 500 ng/ml. 573 
All data N = 3; n = 3. Error bars represent standard error of the mean. *** P < 0.001. In Fig 2Ci 574 
and 2Cii, significance shown is compared to untreated endothelial-pericyte co-cultures; the 575 
difference between “EC alone” and untreated co-cultures is significant at P < 0.0001. 576 
 577 
Fig 3. NS1 has no effect on pericyte viability or migration. (A) Impact of treatment 578 
with purified recombinant DENV-2 NS1 on the viability of endothelial cells (i) or pericytes (ii) 579 
48 h post-treatment relative to untreated cells. N = 4, n = 6. (B) Impact of DENV-2 NS1 on the 580 
migration of pericytes. All values are normalised to the positive control 23 h post-scratch; 581 
positive control is pericytes grown in culture medium containing full complement of growth 582 
factors. N = 3, n = 3. Error bars represent standard error of the mean. Differences between 583 
treated and untreated cells are not statistically significant. 584 
 585 
Fig 4. Pericytes amplify NS1-induced endothelial hyperpermeability via 586 
disrupted paracrine signalling. (A) Impact of treatment with purified recombinant TNF-α or 587 
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DENV-2 NS1 on the permeability of endothelial cell monolayers co-cultured with pericytes 588 
without contact over time as measured by TEER (trans-endothelial electrical resistance). At 589 
each individual time point, TEER values are normalised to untreated endothelial cells cultured 590 
in the absence of pericytes (“EC alone”). (Aii) Experimental set-up of endothelial-pericyte co-591 
cultures for data shown in panel A. (B) NS1-dependent decrease in TEER for endothelial-592 
pericyte co-cultures grown with or without contact shown as absolute magnitude change in 593 
TEER (i) or percentage decrease relative to the respective untreated co-cultures (ii). (C) 594 
Working model for mechanism of pericyte amplification of NS1-induced endothelial 595 
permeability. (i) Under baseline conditions, pericytes support barrier maintenance by 596 
endothelial cells in the microvasculature. (ii) During DENV-2 infection, NS1 secreted into the 597 
circulatory system directly targets endothelial cells to (iii) induce vascular leakage, allowing 598 
NS1 to access pericytes as NS1 levels peak. (iv) Pericyte function is modulated by NS1, 599 
causing pericytes to secrete a paracrine factor (“factor X”) that signals to endothelial cells to 600 
further disrupt the endothelial barrier, resulting in enhanced vascular leakage after NS1 levels 601 
peak. (v) Pericytes recover from transient NS1 effects and normal endothelial-pericyte 602 
signalling is restored to allow cardiovascular recovery. All data N = 3; n = 4. Error bars 603 
represent standard error of the mean. * P < 0.05; ** P < 0.01; *** P < 0.001. In Fig 4A, the 604 
difference between “EC alone” and “untreated” (co-cultures) is significant at P < 0.05; 605 
significant differences from “untreated” (co-cultures) are shown above the line for TNF-α 606 
treatment and below the line for NS1 treatment. 607 
